ABBV vs AEE Stock Comparison

Scores Breakdown

Metric	ABBV	AEE
📈 Growth	26/30	8/30
💰 Profitability	18/20	16/20
🏦 Financial Health	6/20	12/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	8/10	6/10
Overall Score	64/100	52/100

Side-by-Side Summaries

ABBV Analysis	AEE Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory Over 8 quarters, Revenue moved from about $2.17B (2024Q4) to a high of about $2.70B (2025Q3) and ended around $2.09B in 2026Q2. Net income (to parent) rose from about $207M (2024Q4) to roughly $314M (2026Q2), indicating improving profitability despite revenue swings. The trend shows volatility but a constructive late-cycle improvement with strong operating performance in several quarters. 💰 Margins & Cash Flow Operating margins have hovered in the low-to-mid 20s percent on average, with standout quarters in 2025Q1–Q2 (~32–34%) and weaker margins in 2024Q3–Q4 (~9–10%). Net cash from operating activities remained positive in all periods, including a peak near $0.96B (2025Q4); investing cash flow was consistently negative, reflecting capital intensity. Financing activity varied, contributing to liquidity in several quarters. 🛡️ Balance Sheet & Liquidity Total Liabilities run in the mid-to-high $30s billions with equity around $12–14B, implying leverage near 2.5–3x. Long-term Debt remained substantial (roughly $18–20B across periods). Current assets (~~$2.0–$2.7B) vs. current liabilities (~~$3.0–$5.0B) indicate tight near-term liquidity, but the regulated earnings base provides resilience and steady cash generation. ⚠️ Key Drivers & Risks Drivers: Regulated utility framework and capital investment cycle; stable, commodity-insensitive cash flow. Risks: High leverage/interest-rate sensitivity; regulatory/regulatory cost pressures and weather-related demand variability.

ABBV Analysis

AEE Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over 8 quarters, Revenue moved from about $2.17B (2024Q4) to a high of about $2.70B (2025Q3) and ended around $2.09B in 2026Q2. Net income (to parent) rose from about $207M (2024Q4) to roughly $314M (2026Q2), indicating improving profitability despite revenue swings. The trend shows volatility but a constructive late-cycle improvement with strong operating performance in several quarters.

💰 Margins & Cash Flow

Operating margins have hovered in the low-to-mid 20s percent on average, with standout quarters in 2025Q1–Q2 (~32–34%) and weaker margins in 2024Q3–Q4 (~9–10%). Net cash from operating activities remained positive in all periods, including a peak near $0.96B (2025Q4); investing cash flow was consistently negative, reflecting capital intensity. Financing activity varied, contributing to liquidity in several quarters.

🛡️ Balance Sheet & Liquidity

Total Liabilities run in the mid-to-high $30s billions with equity around $12–14B, implying leverage near 2.5–3x. Long-term Debt remained substantial (roughly $18–20B across periods). Current assets (~~$2.0–$2.7B) vs. current liabilities (~~$3.0–$5.0B) indicate tight near-term liquidity, but the regulated earnings base provides resilience and steady cash generation.

⚠️ Key Drivers & Risks

Drivers: Regulated utility framework and capital investment cycle; stable, commodity-insensitive cash flow.
Risks: High leverage/interest-rate sensitivity; regulatory/regulatory cost pressures and weather-related demand variability.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"